Adrian Rawcliffe - Jan 17, 2023 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Role
Chief Executive Officer, Director
Signature
/s/ Adrian George Rawcliffe
Stock symbol
ADAP
Transactions as of
Jan 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/17/2023, 08:01 PM
Previous filing
Jan 12, 2023
Next filing
Jun 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADAP Option to purchase Ordinary Shares Award $0 +4.69M $0.00 4.69M Jan 17, 2023 Ordinary Shares 4.69M $0.31 Direct F1, F2
transaction ADAP Option to purchase Ordinary Shares Award $0 +1.8M $0.00 1.8M Jan 17, 2023 Ordinary Shares 1.8M $0.00 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2 Exercisable as to 1,172,556 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 97,818 Ordinary Shares on January 17, 2027.
F3 The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4 Exercisable as to 449,568 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 449,568 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.
F5 The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.